Login to Your Account



FDA OKs lixisenatide for type 2 diabetics, sets stage for Lantus combo

By Michael Fitzhugh
Staff Writer

Thursday, July 28, 2016

An expected, FDA approval of the type 2 diabetes drug Adlyxin (lixisenatide) finally arrived for Sanofi SA, following initial withdrawal of a new drug application in late 2013.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription